RNF43 and colorectal carcinoma: This publication was followed by an additional article in 2010 reporting on phase I clinical trial testing the safety and immune responses of peptide vaccines derived from RNF43 and 34-kDa translocase of the outer mitochondrial membrane (TOMM34), which were upregulated in more than 80% of CRC.